Evaluation of the clinical efficacy of anti-inflammatory therapy with topical biclotymol-based products

Abstract

Topicality: Acute pharyngeal diseases are one of the most common reasons for patients to visit a doctor. According to the UK, approximately 50% of these diseases account for the appointment of antibacterial agents. Most of these prescriptions are not rational, but doctors use them for several reasons - unreal expectations of treatment, patient pressure/insistence on conducting the desired tests or treatment, the doctor's desire to maintain a better doctor-patient relationship, limited consultation time, diagnostic uncertainty, incorrect collection of historical data and others. Despite these reasons, patients with acute pharyngitis and tonsillitis who seek antibiotic therapy want to reduce their symptoms. Therefore, the search for agents that will significantly improve patients' quality of life during acute pharyngeal diseases is crit ical. Aim: To review the literature on the therapeutic efficacy of topical biclotymol-based products for treating acute pharyngeal diseases. Results and discussion: Most cases of acute pharyngitis should be treated with over-the-counter medicines that are primarily intended to control the symptoms of the disease and improve the patient's quality of life. Biclotymol, enoxolone and lysozyme are novel substances that, at the same time, are safe for resolving pain in viral or bacterial pharyngit is. Biclotymol can be used as monotherapy and in combination with other agents. In the analysed data, biclotymol showed its therapeutic efficacy and safety. Therefore, it is safe to recommend biclotymolbased products for use in acute viral and bacterial pharyngitis or tonsillitis both as monocomponent medicine and fixed-dose combination.